Alembic Pharmaceuticals Limited · NSE:APLLTD

Alembic Pharmaceuticals — Investor Presentation (June 2021)

13 slides from Alembic Pharmaceuticals's investor presentation, June 2021

  1. Slide 1: Alembic Pharmaceuticals Limited Investor presentation – June 2021

    Alembic Pharmaceuticals Limited Investor presentation – June 2021 BSE & NSE: APLLTD

  2. Slide 2: Milestones

    Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir

  3. Slide 3: Financial Highlights

    Financial Highlights INR Bn Particulars Q1 FY22 Q1 FY21 Growth FY21 Net Sales 13.26 13.41 -1% 53.93 EBIDTA Pre R&D 4.06 5.49 -26% 22.52 Margin % 31% 41% 42% R&D 1.67 1.43 17% 6.70 R&D % 13% 11% 12% EBIDTA Post R&D 2.54 4.16 -39% 16.31 Margin % 19% 31% 30% Net Profit 1.65 3.01 -45% 11.78 Capex 1.24 1

  4. Slide 4: Business snapshot – Q1FY22

    Business snapshot – Q1FY22 Formulations Generics Branded API Total US Ex-US India Revenue Q1FY22 (INR Bn) 3.69 1.97 4.81 2.79 13.26 API 28% 21% 21% Vet Generics 4% 43% Q1FY22 Revenue Contribution Acute 14% Branded 15% Speciality 18% 36% Growth Q1FY22 -38% -1% 13% 57% 6% over Q1FY21 Growth Q1FY22 -22

  5. Slide 5: US Generic

    US Generic INR Bn Revenue – Q1 FY22 INR Bn Revenue – Last 5 Years CAGR - 24% 19.76 21.63 5.96 12.88 3.69 9.19 9.20 Q1FY21 Q1FY22 FY17 FY18 FY19 FY20 FY21 Approved ANDAs Derma Injectable 1 17 ➢ Well-established US front end having strong customer base Ophthalmic ➢ Expanded our capabilities to deliver

  6. Slide 6: Ex-US Generics

    Ex-US Generics Revenue : Q1 FY22 INR Bn Revenue – Last 5 Years INR Bn CAGR - 25% 1.97 1.75 7.79 4.94 4.97 Q1FY21 Q1FY22 ➢ Ex-US driven by partnership 3.20 2.86 ➢ Presence in following markets - Europe, Canada, Australia, Brazil and South Africa ➢ The business will focus on new launches across key ma

  7. Slide 7: API

    API Revenue : Q1 FY22 INR Bn Revenue – Last 5 Years INR Bn 2.79 CAGR - 11% 2.64 9.55 7.71 7.08 6.40 6.51 Q1FY21 Q1FY22 ➢ Sales across geographies as preferred supplier ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development l

  8. Slide 8: R&D Significant investments in building capabilities

    R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37 Filing 8.0 13.7% 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 20 19 20 18 * 11 Filings & 4.0 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.3 4.1 contributed by 5 acquisition o

  9. Slide 9: State of the art facilities and infrastructure

    State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Feb’2

  10. Slide 10: Branded Business

    Branded Business Revenue – Q1 FY22 INR Bn Revenue – Last 5 Years CAGR - 5% INR Bn 4.80 15.0 0.53 13.8 14.3 12.5 12.7 3.42 1.92 Vet 0.36 Acute 0.87 Speciality 2.36 1.83 Q1FY21 Q1FY22 FY17 FY18 FY19 FY20 FY21 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢ 17 Ma

  11. Slide 11: Therapy-wise Performance Q1 FY22

    Therapy-wise Performance Q1 FY22 Q1 FY22 Q1 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 19 1.7 8 12 12 1.9 12 16 Gastrology 34 1.3 40

  12. Slide 12: Financials : Generating consistent returns

    Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 16.31 11.78 46.06 39.35 12.13 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.13 4.03 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CAGR - 15% CAGR - 28% CAGR - 31% EBIDTA margin % Cap

  13. Slide 13: Thank you

    Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu

Alembic Pharmaceuticals — Investor Presentation (June 2021) on 6ix